Trial Profile
Safety, Tolerability and Pharmacokinetics of Single Rising Oral Doses of BI 411034 (PIB) in Healthy Male Volunteers (Randomised, Single-blind, Placebocontrolled Within Dose Groups, Phase I Study)
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 07 Nov 2021
Price :
$35
*
At a glance
- Drugs BI 411034 (Primary)
- Indications Unspecified
- Focus Adverse reactions; Pharmacogenomic
- Sponsors Boehringer Ingelheim
- 11 Apr 2014 New trial record